The programme includes oral and poster presentations from all the students, talks from high-profile keynote speakerscareer development workshops, and talks from the participating institutes.

We are preparing all the details to make the IPSCC 2022 an entertaining and dynamic environment!

While students from all years are invited to participate, students in the more advanced stages of their PhD are particularly encouraged to attend and give an oral presentation of their work. All attendees will have to present their research by giving a talk or presenting a poster.

We are honoured to host Dr Dafna Bar-Sagi (online lecture), Dr Susanne Schlisio and Dr Rita Fior, three extraordinary scientists in Cancer Research, as our keynote speakers.

Dafna Bar-Sagi, PhD, is the executive vice president and vice dean for science, chief scientific officer of NYU Langone Health. She is also the Saul J. Farber Professor of Biochemistry and Molecular Pharmacology.

Dr. Bar-Sagi is a world-renowned cancer biologist whose research has had a major impact on the understanding of mechanisms that control tumor initiation and progression.  The focus of her work is the Ras oncogene and its role in the regulation of cell proliferation and survival, tumor immunity, cellular metabolism, and cell-to-cell signaling. Her laboratory is credited with identifying key molecular events that mediate Ras activation by extracellular signals and regulate its intracellular activity. She was also the first to show that oncogenic KRas is directly involved in conferring immune suppression – a discovery that establishes a new mechanistic paradigm for therapeutic interventions.  A current focus of her laboratory is on elucidating the contribution of oncogenic Ras to the metabolic adaptation of tumor cells.  Her efforts in this area have established a new paradigm for nutrient delivery into tumor cells involving the scavenging of extracellular protein by macropinocytosis.   This nutrient delivery mechanism has broad implications for understanding the metabolic vulnerabilities of Ras-driven tumors.

Dr. Bar-Sagi is the recipient of numerous honors and awards, including a Member of the American Academy of Arts and Sciences, a Member of the National Academy of Sciences, a Fellow of the American Association for Cancer Research, an IUBMB Jubilee Lectureship Award, an NCI Outstanding Investigator Award, an AACR-WICR Memorial Award, and an NCI Merit Award. 

Title: Oncogenic Ras-dependent determinants of tumor fitness

Susanne Schlisio, Ph.D., is a cancer biologist with extensive experience in sympathoadrenal nervous system malignancies, neuronal development and cancer mouse models. She performed her PhD studies at Duke University Medical School in 2002 in cancer research. In 2008, she completed her postdoctoral research at the Dana Farber Cancer Institute at the Harvard Medical School. As a postdoctoral researcher in the laboratory of Dr William G. Kaelin, Jr. she was part of the team discovering how cells adapt to changes in oxygen availability and how this process is directly linked to cancer discoveries that now have been recognized with the award of the Nobel Prize to Dr Kaelin. In 2008, she was a recipient of an internationally competitive member position at the Ludwig Cancer Institute Stockholm to start her research group. Since 2017, she is a faculty at the Department of Microbiology Tumor and Cell Biology at Karolinska Institutet, Stockholm. Her current and future work includes the identification of novel oxygen-sensing pathways that are implicated in malignant transformation, with focus on cancer arising from the sympathoadrenal lineage, such as neuroblastoma and pheochromocytoma. Furthermore, her laboratory developed a new analytic and experimental approach based on single nuclei transcriptomics and mass spectrometry to explore intra-tumour heterogeneity and plasticity in childhood neuroblastoma and pheochromocytoma. Her lab generated novel tumour mouse model systems and includes human tumours to perform comparative differentiation trajectory analysis, make predictions and, finally, perform preliminary validations of envisioned tumour differentiation strategies.

Title: Dissecting developmental programs reveal causes of heterogeneity and plasticity in childhood neuroblastoma and pheochromocytoma

Rita Fior, Ph.D., is a highly motivated cancer biologist and a group leader at the prestigious Champalimaud Centre, in Lisbon. During her PhD she studied the Notch downstream events that control the balance between neural differentiation and progenitor maintenance and generated an unstable Notch reporter to study Notch signalling in real-time. During her post-doc, she started using zebrafish as a model organism and found a transcription-based negative feedback loop that allows the coordination between 3 major events during zebrafish segmentation: differentiation, cell movement and stem cell maintenance.​ 

Recently, she became interested in cancer; she and her Lab are navigating the path toward personalised medicine in cancer therapy using zebrafish models. One of the major goals in her Lab is to develop a test to help MDs choose the best available therapy for each individual patient, using zebrafish Avatars. In parallel, her  Lab also investigates the cellular and molecular interactions that occur during innate tumour rejection/evasion using the zebrafish xenograft model. They have recently found that human tumour cells are able to reconstitute different tumour microenvironments and generate hot or cold TME. Her goal is to understand these processes and use the zebrafish xenografts to discover new therapies to be combined with immunotherapy.

Title: Zebrafish Avatars for personalized medicine and to study cancer innate immune evasion and rejection

The IPSCC 2022 will host 4 career-oriented workshops, aiming at providing additional tools for the participating students to develop their future careers:

Check more details on our registration page.